The Rapid Influenza Diagnostic Tests Market to Grow On a Digitally Irrevocable Note

The Rapid Influenza Diagnostic Tests Market is expected to climb up the ladder of persistence in the next decade. With various healthcare apps on the anvil, there are also mindfulness apps being tabled. They fall in the category of "Wellness apps". With the world wishing for the post-Covid era to function smoothly, these wellness apps are expected to take the healthcare vertical by storm further.

As per Persistence Market Research's latest revised industry analysis, the global rapid influenza diagnostic tests market is expected to witness high growth during the forecast period. The market is expected to top US$ 2 Bn by 2031, which reflects a CAGR of around 8.7% for the decade.

Influenza is recognized as a major source of illness and mortality in humans, prompting the development and implementation of diagnostics aimed at decreasing the health and economic consequences. Influenza causes serious illness or death, primarily in high-risk people.

With the start of the flu season comes an increase in antibiotic use, elevating the danger of antibiotic resistance in the body. The speedy turn-around times of devices used at point-of-care aid in the preparation of a targeted and successful treatment plan based on test results. Rapid influenza diagnostic tests have a short turnaround time, with some offering results in under 15 minutes. As a result, adoption of rapid influenza diagnostic tests helps prevent over-prescription of antibiotics as well as avoid the core cause of bacterial resistance and its negative consequences.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/31040

The current COVID-19 pandemic has also boosted demand for rapid influenza diagnostic tests. When compared to influenza, COVID-19 has a similar illness presentation - both viruses induce respiratory problems. Furthermore, both are spread via touch, droplets, and fomites. COVID-19 patients have been misdiagnosed with influenza in the past, which has increased demand for virus rapid detection kits.

Emergence of smartphone-based disease screening has increased market revenue. The Human Genome Project and breakthroughs in molecular and biomedical technology have led to the creation of a plethora of assays and technologies useful for the diagnosis and monitoring of influenza infections. These new technologies, which are based on genomic (PCR-based) and proteomic (microarray-based detection) techniques, aid in the discovery of novel influenza viruses. They also allow for improved surveillance and rapid detection of infectious diseases, which presents a good business opportunity for market players.

Company Profiles:

Thermo Fisher Scientific
Hologic
Quidel Corporation
F. Hoffmann-La Roche AG
Abbott Laboratories
Becton Dickinson and Company
Danaher Corporation
Meridian Bioscience
bioMérieux SA
Luminex Corporation
Siemens Healthineers AG
GenMark Diagnostics
Sekisui Diagnostics
LLC altona Diagnostics GmbH
SA Scientific
ELITech Group

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/31040

Key Takeaways from Market Study

By principle, immunochromatographic assays are set hold high share of 66.8% in 2021, expanding at 6.1% CAGR over the forecast period.
By test type, influenza A+B test is expected to hold 79% market share, and is expected to continue growing at similar trend due to its benefits such as simple to use and rapid diagnosis.
By sample, the nasopharyngeal swab segment is expected to 31% market share, and nasopharyngeal aspirate is the second-leading segment, which accounts for 27.5%.
By end user, office-based settings account for nearly 22.5% market share.
By region, North America held 36.6% of the global market share in 2021.

"Rising demand for rapid disease diagnosis, increasing influenza prevalence, and increased research for diagnostic technologies are expected to provide growth opportunities for market players," says an analyst of Persistence Market Research.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/31040

Market Competition

Leading market players are focusing on product approvals and launches as a key growth strategy for global expansion, thereby enhancing their market presence. They are also emphasizing on entering into strategic partnerships with local suppliers and distributors to expand product reach.

In March 2021, Abbott received an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its AlinityTM m Resp-4-Plex molecular assay, which can identify and discriminate SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) all in one test. This test has received CE certification and is available in countries other than the United States.
In February 2020, the FDA granted Quidel an Emergency Use Authorization (EUA) to market its Sofia® 2 Flu + SARS Antigen FIA for the rapid, simultaneous qualitative identification, and characterization of nucleocapsid protein antigens from SARS-CoV-2, influenza A, and influenza B in direct nasopharyngeal (NP) and nasal (NS) swab samples from persons suspected of respiratory viral infection consistent with COVID-19.
In August 2017, Meridian Bioscience, Inc. announced the expansion of its ImmunoCard STAT!® product line with the addition of ImmunoCard STAT! FLU A&B.

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/rapid-influenza-diagnostic-tests-market.asp

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the rapid influenza diagnostics tests market in its latest study, presenting historical demand assessment of 2016 - 2020 and projections for 2021 - 2031.

The research study is based on the principle (immunochromatographic assays, immunofluorescence assays and nucleic acid amplification test (NAAT)), test type (influenza A test, influenza B test and influenza A+B test), sample (throat swab, nasal swab, nasal aspirate, nasal wash, nasopharyngeal swab, nasopharyngeal aspirate, nasopharyngeal wash and others) and end user (hospitals, diagnostic centers, nursing homes, office-based settings, urgent care centers, retail pharmacy clinics, schools & universities, public health camps and others (cruise ships, correctional facilities, etc.) in seven prominent regions.

Related Reports:

Trichomonas Rapid Testing Market - https://www.persistencemarketresearch.com/market-research/trichomonas-rapid-testing-market.asp

Host Cell Contaminant Testing Market - https://www.persistencemarketresearch.com/market-research/host-cell-contaminant-testing-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.